Healthtech is its own marketing discipline: the buying cycle is long, the committee is large, and the deciding factor is proven clinical outcomes, not brand messaging or paid reach.
A health system, payer, or clinic does not impulse-buy software. The decision runs through clinicians, IT, security, and procurement over many months, and it rarely starts with a blank slate. By the time a buyer agrees to a demo, they have already read the case studies, checked who else uses you, and formed a preference. Most of that happens quietly, before anyone fills out a form.
That is why a generic “startup growth” playbook underperforms here. The intent is slower and more skeptical, the stakeholders are many, and the failure points are specific: a thin case-study library, a product the AI answer never names, a security question your content does not answer, a lead that sits for two days while a buyer talks to someone else. We build around those exact moments, and every claim on this page is backed by a real source, listed at the bottom.
The case for doing this differently is not our opinion. It is what the data says, every figure sourced below.
The winner is on the shortlist before you ever talk.
Healthtech buying is a process of confirmation, not selection. In 6sense’s research, 95% of the time the winning vendor is already on the buyer’s Day One shortlist, and roughly four out of five deals go to the pre-contact favorite. By the time a committee forms around a purchase, most of the deciding has already happened in the quiet research phase that came before it.
The takeaway is not “run more ads.” It is “be the default before the buyer starts shopping.” That means showing up in the research phase with the proof a clinical or payer buyer is looking for, so that when the committee forms, your name is the one they were going to confirm. A program that only chases active demand is fighting for the 5% of deals that are still up for grabs at the end.
Healthtech buying is confirmation, not selection. The job is to be the default before the evaluation starts.
95% of the time the winning vendor is already on the buyer’s Day One shortlist.
The shortlist is set before contact
Proof closes the deal. Brand messaging does not.
Healthtech vendor selection runs on evidence. In HIMSS healthcare IT buyer research, the number-one selection factor was proven success with other healthcare customers, with interoperability and security topping the list right behind it. And 86% of buyers want to see product demos and vendor-created content like case studies and white papers, not slogans.
For a buyer who has to justify the spend to a committee and de-risk it for their organization, your case-study library and demo are the load-bearing assets. We treat them that way: a steady pipeline of outcome stories, security and interoperability answers built into the content, and demo paths that move a skeptical evaluator forward instead of dropping them into a generic “contact us.” The proof is what gets you onto the shortlist and what keeps you there.
Buyers want demos and case studies. Build the proof, not the slogan.
Demos and case studies decide the buy
And the #1 selection factor is proven success with other healthcare customers, ahead of brand or price.
Source: HIMSS Healthcare IT Buyer research (via Health Launchpad)AI search is the new first round of vendor research.
Discovery in your category is moving into the AI answer. Pew Research found that about 18% of Google searches now return an AI summary, and when one appears, people click a traditional result far less often: 8% of the time versus 15% with no summary. They click a source cited inside the AI answer only 1% of the time. For B2B technology specifically, AI Overview coverage more than doubled in a year, from 36% to 82% of queries, so a healthtech startup invisible in AI answers is invisible across most of its category searches.
Being on page one is no longer the finish line; you have to be the vendor the AI assembles and names. The work is structural: schema, entity clarity, and pages built to be quoted, not just ranked. Yet traditional organic search still carries the load, accounting for the vast majority of conversions while AI referrals sit under 1% of traffic, so we treat AEO as a layer on top of a healthy SEO foundation, not a replacement for it.
Be the vendor the AI names, on a foundation of organic search that still carries the traffic.
AI answers took over B2B tech search in a year
Clinicians and payers move your product, not influencers.
For consumer-facing digital health, the channel that drives adoption is endorsement, not promotion. EMARKETER found that 58% of digital health tool users said their healthcare provider or insurer influenced their usage, while just 4% of non-users said a social influencer promotion would get them to try a tool. The people who move a patient toward your product are the ones the patient already trusts with their care.
This reframes the playbook away from pure DTC spend. The marketing that matters is the kind that earns clinical and payer credibility and shows up in the channels buyers trust: provider-facing proof, review presence, and content structured so the AI recommendation engines surface you. We build for the people who influence the patient’s choice, not the ones who are cheapest to reach.
Clinical and payer endorsement moves adoption. A social influencer barely registers.
Who gets a tool tried
You can’t outspend this market, only out-convert it.
Healthtech funding is consolidating toward the players who can outspend you. In Rock Health’s 2025 year-end report, AI-enabled digital health companies captured 54% of total funding, up from 37% the year before. When the best-capitalized incumbents are AI-positioned and flush, matching them dollar for dollar on paid channels is not a strategy a startup can win.
The edge is efficiency. In B2B SaaS, organic search acquires customers at a $205 CAC versus $341 for paid, and organic beats paid in almost every case. We point the budget at the compounding owned channels (SEO, content, AEO, and reputation) that lower the cost of every future case study and demo, and we report on pipeline and signed accounts, not vanity traffic.
Organic beats paid on cost in almost every case. Compounding owned channels are the lever.
Organic acquires customers cheaper
Long cycles still reward the firm that answers fast.
The healthtech buying cycle is long: in HIMSS research, half of buyers reported a cycle exceeding 19 months, which means demand generation has to nurture across many months rather than convert on first touch. That is a reason to build content and reputation that compound, not a reason to be slow when a buyer finally raises a hand.
Because when the inbound lead does come, speed is a measurable revenue lever. Harvard Business Review found that contacting a lead within an hour makes you nearly seven times more likely to qualify it than waiting even an hour longer, and more than 60 times more likely than waiting 24 hours, yet the average response time was 42 hours. We pair patient, compounding demand generation with fast, tracked intake, so the lead you spent months earning is not lost in the two days it takes a competitor to call back first.
AI-enabled digital health companies captured 54% of total funding (up from 37% last year).
Rock Health, 2025 year-end digital health funding report
The #1 selection factor was ‘proven success with other healthcare customers’, with interoperability and security also topping the list.
Adam Turinas, Health Launchpad, on HIMSS healthcare IT buyer research
AI search is the fastest-growing channel we’ve ever tracked. However, growth and quality are two different things.
Jim Yu, Founder and CEO, BrightEdge
Want to be on the shortlist before the evaluation starts?
Healthtech buyers decide who they trust long before they take a meeting, and they decide on proof: case studies, demos, clinical credibility, and a presence in both organic and AI search. We build the compounding program that puts your product in that research phase and keeps it there, then back it with intake fast enough to win the lead you worked months to earn. Tell us where you are, and we’ll show you what the next two quarters look like.
Frequently asked
Why is healthtech marketing different from general B2B SaaS marketing?
How early do healthtech buyers really decide on a vendor?
Does AI search matter for a healthtech startup, or is SEO still enough?
Should we lean on influencers or DTC ads to drive product adoption?
If the buying cycle is over a year, why does response speed matter?
What does MoonSauce report on for a healthtech engagement?
Every figure on this page comes from a primary platform, an independent study, or a named industry source. No competing-agency stats, no made-up numbers.
- 6sense B2B Buyer Experience Report 2025
- HIMSS Healthcare IT Buyer research (via Health Launchpad)
- Pew Research Center, 2025
- BrightEdge (via Search Engine Journal)
- BrightEdge, organic vs AI referral traffic
- EMARKETER, digital health adoption drivers
- First Page Sage, Average CAC by Industry (B2B Edition)
- Rock Health, 2025 year-end digital health funding overview
- Harvard Business Review, “The Short Life of Online Sales Leads”
